FIND established its presence in India in 2007, starting with a memorandum of understanding with the Central TB Division, Ministry of Health and Family Welfare, to demonstrate and introduce new, rapid, quality-assured tests for tuberculosis (TB) at affordable prices for the public health sector.
Our activities in India initially focused on evaluation and demonstration studies of new diagnostic tools that FIND had co-developed with partners, including liquid culture and drug susceptibility testing, rapid speciation, molecular line probe assay, LED-based fluorescence microscopy, and Xpert MTB/RIF.
The data from these studies formed part of the body of evidence that ultimately enabled their endorsement by the World Health Organization (WHO). India’s Revised National TB Control Programme (RNTCP) also used these data to help formulate its guidelines for the detection and management of drug-resistant TB.
More than ten years on, with a renewed mission and a broader scope of work, FIND’s portfolio in India has expanded to include hepatitis C and antimicrobial resistance alongside a strong continued focus on TB diagnosis.